Intravenous vitamin C and cancer: A systematic review

Integrative Cancer Therapies

Volumn 13, Issue 4, 2014, Pages 280-300

  Fritz, Heidi ^a   Flower, Gillian ^b   Weeks, Laura ^b   Cooley, Kieran ^a,c   Callachan, Michael ^a   McGowan, Jessie ^a   Skidmore, Becky ^a   Kirchner, Leesa ^d   Seely, Dugald ^a,b,e  

^a CANADIAN COLLEGE OF NATUROPATHIC MEDICINE   (Canada)

^b Ottawa Integrative Cancer Centre   (Canada)

^c UNIVERSITY OF TORONTO   (Canada)

^d Carp Ridge Natural Health Clinic Carp   (Canada)

^e OTTAWA HOSPITAL RESEARCH INSTITUTE   (Canada)

Author keywords

ascorbic acid; cancer; chemotherapy; integrative oncology; interactions; intravenous vitamin C; naturopathic oncology; quality of life; systematic review; vitamin C

Indexed keywords

ASCORBIC ACID; CARBOPLATIN; ERLOTINIB; GEMCITABINE; PACLITAXEL; ANTINEOPLASTIC AGENT;

ANTINEOPLASTIC ACTIVITY; CANCER CHEMOTHERAPY; CANCER PATIENT; CANCER RADIOTHERAPY; CANCER RECURRENCE; CANCER STAGING; CANCER SURVIVAL; CHEMOTHERAPY INDUCED NAUSEA AND VOMITING; CLINICAL PRACTICE; COMPUTER ASSISTED EMISSION TOMOGRAPHY; CONSTIPATION; CYTOREDUCTIVE SURGERY; DRUG EFFICACY; DRUG HALF LIFE; DRUG MEGADOSE; DRUG SAFETY; FATIGUE; HEADACHE; HUMAN; INJECTION SITE PAIN; INSOMNIA; INTERVENTION STUDY; MALIGNANT NEOPLASTIC DISEASE; MAXIMUM PLASMA CONCENTRATION; OBSERVATIONAL STUDY; OVARY CANCER; OVERALL SURVIVAL; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; SYSTEMATIC REVIEW; TREATMENT RESPONSE; VITAMIN BLOOD LEVEL; XEROSTOMIA; INTRAVENOUS DRUG ADMINISTRATION; NEOPLASMS; SURVIVAL RATE;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; ASCORBIC ACID; HUMANS; INFUSIONS, INTRAVENOUS; NEOPLASMS; QUALITY OF LIFE; SURVIVAL RATE;

EID: 84904171879     PISSN: 15347354     EISSN: 1552695X     Source Type: Journal    
DOI: 10.1177/1534735414534463     Document Type: Review

References (119)

1. Padayatty SJ, Sun AY, Chen Q, Espey MG, Drisko J, Levine M. Vitamin C: intravenous use by complementary and alternative medicine practitioners and adverse effects. PLoS One. 2010 ; 5: e11414
2. Padayatty SJ, Riordan HD, Hewitt SM, Katz A, Hoffer LJ, Levine M. Intravenously administered vitamin C as cancer therapy: three cases. CMAJ. 2006 ; 174: 937-942
3. Stephenson CM, Levin RD, Spector T, Lis CG. Phase I clinical trial to evaluate the safety, tolerability, and pharmacokinetics of high-dose intravenous ascorbic acid in patients with advanced cancer. Cancer Chemother Pharmacol. 2013 ; 72: 139-146
4. Mikirova N, Casciari J, Rogers A, Taylor P. Effect of high-dose intravenous vitamin C on inflammation in cancer patients. J Transl Med. 2012 ; 10: 189
5. Monti DA, Mitchell E, Bazzan AJ, et al. Phase I evaluation of intravenous ascorbic acid in combination with gemcitabine and erlotinib in patients with metastatic pancreatic cancer. PLoS One. 2012 ; 7: e29794
6. Vollbracht C, Schneider B, Leendert V, Weiss G, Auerbach L, Beuth J. Intravenous vitamin C administration improves quality of life in breast cancer patients during chemo-/radiotherapy and aftercare: results of a retrospective, multicentre, epidemiological cohort study in Germany. In Vivo. 2011 ; 25: 983-990
7. Welsh JL, Wagner BA, van't Erve TJ, et al. Pharmacological ascorbate with gemcitabine for the control of metastatic and node-positive pancreatic cancer (PACMAN): results from a phase I clinical trial. Cancer Chemother Pharmacol. 2013 ; 71: 765-775
8. Takahashi H, Mizuno H, Yanagisawa A. High-dose intravenous vitamin C improves quality of life in cancer patients. Personalized Medicine Universe. 2012 ; 2 (1). 49-53
9. Cameron E, Pauling L. The orthomolecular treatment of cancer. I. The role of ascorbic acid in host resistance. Chem Biol Interact. 1974 ; 9: 273-283
10. Cameron E, Campbell A. The orthomolecular treatment of cancer. II. Clinical trial of high-dose ascorbic acid supplements in advanced human cancer. Chem Biol Interact. 1974 ; 9: 285-315
11. Cameron E, Pauling L. Supplemental ascorbate in the supportive treatment of cancer: prolongation of survival times in terminal human cancer. Proc Natl Acad Sci U S A. 1976 ; 73: 3685-3689
12. Abdel-Latif MM, Raouf AA, Sabra K, Kelleher D, Reynolds JV. Vitamin C enhances chemosensitization of esophageal cancer cells in vitro. J Chemother. 2005 ; 17: 539-549
13. Nagy B, Mucsi I, Molnar J, Varga A, Thurzo L. Chemosensitizing effect of vitamin C in combination with 5-fluorouracil in vitro. In Vivo. 2003 ; 17: 289-292
14. Fromberg A, Gutsch D, Schulze D, et al. Ascorbate exerts anti-proliferative effects through cell cycle inhibition and sensitizes tumor cells towards cytostatic drugs. Cancer Chemother Pharmacol. 2011 ; 67: 1157-1166
15. Levine M, Padayatty SJ, Espey MG. Vitamin C: a concentration-function approach yields pharmacology and therapeutic discoveries. Adv Nutr. 2011 ; 2: 78-88
16. Chen Q, Espey MG, Sun AY, et al. Ascorbate in pharmacologic concentrations selectively generates ascorbate radical and hydrogen peroxide in extracellular fluid in vivo. Proc Natl Acad Sci U S A. 2007 ; 104: 8749-8754
17. Padayatty SJ, Sun H, Wang Y, et al. Vitamin C pharmacokinetics: implications for oral and intravenous use. Ann Intern Med. 2004 ; 140: 533-537
18. Putchala MC, Ramani P, Sherlin HJ, Premkumar P, Natesan A. Ascorbic acid and its pro-oxidant activity as a therapy for tumours of oral cavity - a systematic review. Arch Oral Biol. 2013 ; 58: 563-574
19. Chen Q, Espey MG, Krishna MC, et al. Pharmacologic ascorbic acid concentrations selectively kill cancer cells: action as a pro-drug to deliver hydrogen peroxide to tissues. Proc Natl Acad Sci U S A. 2005 ; 102: 13604-13609
20. Deubzer B, Mayer F, Kuci Z, et al. H2O2-mediated cytotoxicity of pharmacologic ascorbate concentrations to neuroblastoma cells: potential role of lactate and ferritin. Cell Physiol Biochem. 2010 ; 25: 767-774
21. Chen Q, Espey MG, Sun AY, et al. Pharmacologic doses of ascorbate act as a prooxidant and decrease growth of aggressive tumor xenografts in mice. Proc Natl Acad Sci U S A. 2008 ; 105: 11105-11109
22. Fromberg A, Gutsch D, Schulze D, et al. Ascorbate exerts anti-proliferative effects through cell cycle inhibition and sensitizes tumor cells towards cytostatic drugs. Cancer Chemother Pharmacol. 2011 ; 67: 1157-1166
23. Riordan NH, Riordan HD, Meng X, Li Y, Jackson JA. Intravenous ascorbate as a tumor cytotoxic chemotherapeutic agent. Med Hypotheses. 1995 ; 44: 207-213
24. Du J, Martin SM, Levine M, et al. Mechanisms of ascorbate-induced cytotoxicity in pancreatic cancer. Clin Cancer Res. 2010 ; 16: 509-520
25. Corpe CP, Eck P, Wang J, Al-Hasani H, Levine M. Intestinal dehydroascorbic acid (DHA) transport mediated by the facilitative sugar transporters, GLUT2 and GLUT8. J Biol Chem. 2013 ; 288: 9092-9101
26. Vera JC, Rivas CI, Zhang RH, Farber CM, Golde DW. Human HL-60 myeloid leukemia cells transport dehydroascorbic acid via the glucose transporters and accumulate reduced ascorbic acid. Blood. 1994 ; 84: 1628-1634
27. Kc S, Carcamo JM, Golde DW. Vitamin C enters mitochondria via facilitative glucose transporter 1 (Glut1) and confers mitochondrial protection against oxidative injury. FASEB J. 2005 ; 19: 1657-1667
28. Astuya A, Caprile T, Castro M, et al. Vitamin C uptake and recycling among normal and tumor cells from the central nervous system. J Neurosci Res. 2005 ; 79: 146-156
29. Agus DB, Gambhir SS, Pardridge WM, et al. Vitamin C crosses the blood-brain barrier in the oxidized form through the glucose transporters. J Clin Invest. 1997 ; 100: 2842-2848
30. Salani B, Marini C, Rio AD, et al. Metformin impairs glucose consumption and survival in Calu-1 cells by direct inhibition of hexokinase-II. Sci Rep. 2013 ; 3: 2070
31. Szablewski L. Expression of glucose transporters in cancers. Biochim Biophys Acta. 2013 ; 1835: 164-169
32. Fritz H, Kennedy D, Fergusson D, et al. Vitamin A and retinoid derivatives for lung cancer: a systematic review and meta analysis. PLoS One. 2011 ; 6: e21107
33. Altman DG, Schulz KF, Moher D, et al. The revised CONSORT statement for reporting randomized trials: explanation and elaboration. Ann Intern Med. 2001 ; 134: 663-694
34. Gagnier JJ, Boon H, Rochon P, Moher D, Barnes J, Bombardier C. Recommendations for reporting randomized controlled trials of herbal interventions: explanation and elaboration. J Clin Epidemiol. 2006 ; 59: 1134-1149
35. WellsGASheaBO'ConnellD. The Newcastle-Ottawa Scale (NOS) for assessing the quality of nonrandomised studies in meta-Analyses. http://www.ohri.ca/ programs/clinical-epidemiology/oxford.htm. Accessed September 24, 2010.
36. Higgins JP, Altman DG, Gotzsche PC, et al. The Cochrane Collaboration's tool for assessing risk of bias in randomised trials. BMJ. 2011 ; 343: d5928
37. Ma Y, Chapman J, Levine M, Polireddy K, Drisko J, Chen Q. High-dose parenteral ascorbate enhanced chemosensitivity of ovarian cancer and reduced toxicity of chemotherapy. Sci Transl Med. 2014 ; 6: 222ra218
38. Hoffer LJ, Levine M, Assouline S, et al. Phase I clinical trial of i.v. ascorbic acid in advanced malignancy. Ann Oncol. 2008 ; 19: 1969-1974
39. Mikirova NA, Jackson JA, Riordan NH. The effect of high dose IV vitamin C on plasma antioxidant capacity and level of oxidative stress in cancer patients and healthy subjects. J Orthomol Med. 2007 ; 22: 153-160
40. Riordan HD, Casciari JJ, Gonzalez MJ, et al. A pilot clinical study of continuous intravenous ascorbate in terminal cancer patients. P R Health Sci J. 2005 ; 24: 269-276
41. Stephenson CM, Levin RD, Lis CG. Phase 1 trial of high-dose intravenous vitamin C treatment for patients with cancer. J Am Osteopath Assoc. 2007 ; 107: 212-213
42. Yeom CH, Jung GC, Song KJ. Changes of terminal cancer patients' health-related quality of life after high dose vitamin C administration. J Korean Med Sci. 2007 ; 22: 7-11
43. Robitaille L, Mamer OA, Miller WH, et al. Oxalic acid excretion after intravenous ascorbic acid administration. Metabolism. 2009 ; 58: 263-269
44. Cameron E, Campbell A., Innovation vs. quality control: an "unpublishable" clinical trial of supplemental ascorbate in incurable cancer. Med Hypotheses. 1991 ; 36: 185-189
45. Cameron E, Pauling L. Supplemental ascorbate in the supportive treatment of cancer: reevaluation of prolongation of survival times in terminal human cancer. Proc Natl Acad Sci U S A. 1978 ; 75: 4538-4542
46. Drisko JA, Chapman J, Hunter VJ. The use of antioxidants with first-line chemotherapy in two cases of ovarian cancer. J Am Coll Nutr. 2003 ; 22: 118-123
47. Riordan HD, Jackson JA, Riordan NH, Schultz M. High-dose intravenous vitamin C in the treatment of a patient with renal cell carcinoma of the kidney. J Orthomol Med. 1998 ; 13: 72-73
48. Riordan HD, Jackson JA, Schultz M. Case study: high-dose intravenous vitamin C in the treatment of a patient with adenocarcinoma of the kidney. J Orthomol Med. 1990 ; 5: 5-7
49. Riordan HD, Riordan NH, Jackson JA, et al. Intravenous vitamin C as a chemotherapy agent: a report on clinical cases. P R Health Sci J. 2004 ; 23: 115-118
50. Riordan N, Jackson JA, Riordan HD. Intravenous vitamin C in a terminal cancer patient. J Orthomol Med. 1996 ; 11: 80-82
51. De Oliveira JLG. A nutritious cocktail for the treatment of melanoma: a case report. J Orthomol Med. 1998 ; 13: 176-178
52. Jackson JA, Riordan HD, Bramhall NL, Neathery S. Sixteen-year history with high dose intravenous vitamin C treatment for various types of cancer and other diseases. J Orthomol Med. 2002 ; 17: 117-119
53. Cameron E, Campbell A, Jack T. The orthomolecular treatment of cancer. III. Reticulum cell sarcoma: double complete regression induced by high-dose ascorbic acid therapy. Chem Biol Interact. 1975 ; 11: 387-393
54. Campbell A. Development of a papillary thyroid carcinoma in a patient while on high dosage ascorbic acid therapy. Chem Biol Interact. 1980 ; 30: 305-308
55. Campbell A, Jack T, Cameron E. Reticulum cell sarcoma: two complete "spontaneous" regressions, in response to high-dose ascorbic acid therapy. A report on subsequent progress. Oncology. 1991 ; 48: 495-497
56. Campbell A, Jack T. Acute reactions to mega ascorbic acid therapy in malignant disease. Scott Med J. 1979 ; 24: 151-153
57. Jackson JA, Riordan HD, Hunninghake RE, Riordan N. High dose intravenous vitamin C and long time survival of a patient with cancer of head of the pancreas. J Orthomol Med. 1995 ; 10: 87-88
58. Dammacco F, Benvestito S. Effects of cefodizime on non-specific immune functions in patients with multiple myeloma. Infection. 1992 ; 20: S64 - S66
59. Berenson JR, Matous J, Swift RA, Mapes R, Morrison B, Yeh HS. A phase I/II study of arsenic trioxide/bortezomib/ascorbic acid combination therapy for the treatment of relapsed or refractory multiple myeloma. Clin Cancer Res. 2007 ; 13: 1762-1768
60. Abou-Jawde RM, Reed J, Kelly M, et al. Efficacy and safety results with the combination therapy of arsenic trioxide, dexamethasone, and ascorbic acid in multiple myeloma patients: a phase 2 trial. Med Oncol. 2006 ; 23: 263-272
61. Berenson JR, Boccia R, Siegel D, et al. Efficacy and safety of melphalan, arsenic trioxide and ascorbic acid combination therapy in patients with relapsed or refractory multiple myeloma: a prospective, multicentre, phase II, single-Arm study. Br J Haematol. 2006 ; 135: 174-183
62. Welch JS, Klco J, Gao F, Hassan A, Vij R.. Paper presented at: Blood Conference: 52nd Annual Meeting of the American Society of Hematology, ASH 2010 ; 2010 Orlando, FL ; 2010..
63. Burris HA, Moore MJ, Andersen J, et al. Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial. J Clin Oncol. 1997 ; 15: 2403-2413
64. Park JH, Davis KR, Lee G, et al. Ascorbic acid alleviates toxicity of paclitaxel without interfering with the anticancer efficacy in mice. Nutr Res. 2012 ; 32: 873-883
65. An SH, Kang JH, Kim DH, Lee MS. Vitamin C increases the apoptosis via up-regulation p53 during cisplatin treatment in human colon cancer cells. BMB Rep. 2011 ; 44: 211-216
66. Espey MG, Chen P, Chalmers B, et al. Pharmacologic ascorbate synergizes with gemcitabine in preclinical models of pancreatic cancer. Free Radic Biol Med. 2011 ; 50: 1610-1619
67. Ranzato E, Biffo S, Burlando B. Selective ascorbate toxicity in malignant mesothelioma: a redox Trojan mechanism. Am J Respir Cell Mol Biol. 2011 ; 44: 108-117
68. Maramag C, Menon M, Balaji KC, Reddy PG, Laxmanan S. Effect of vitamin C on prostate cancer cells in vitro: effect on cell number, viability, and DNA synthesis. Prostate. 1997 ; 32: 188-195
69. Hong SW, Lee SH, Moon JH, et al. SVCT-2 in breast cancer acts as an indicator for L-Ascorbate treatment. Oncogene. 2013 ; 32: 1508-1517
70. Hong SW, Jin DH, Hahm ES, et al. Ascorbate (vitamin C) induces cell death through the apoptosis-inducing factor in human breast cancer cells. Oncol Rep. 2007 ; 18: 811-815
71. Bhat SH, Azmi AS, Hanif S, Hadi SM. Ascorbic acid mobilizes endogenous copper in human peripheral lymphocytes leading to oxidative DNA breakage: a putative mechanism for anticancer properties. Int J Biochem Cell Biol. 2006 ; 38: 2074-2081
72. Park S, Han SS, Park CH, et al. L-Ascorbic acid induces apoptosis in acute myeloid leukemia cells via hydrogen peroxide-mediated mechanisms. Int J Biochem Cell Biol. 2004 ; 36: 2180-2195
73. Chen P, Yu J, Chalmers B, et al. Pharmacological ascorbate induces cytotoxicity in prostate cancer cells through ATP depletion and induction of autophagy. Anticancer Drugs. 2012 ; 23: 437-444
74. Vuyyuri SB, Rinkinen J, Worden E, Shim H, Lee S, Davis KR. Ascorbic acid and a cytostatic inhibitor of glycolysis synergistically induce apoptosis in non-small cell lung cancer cells. PLoS One. 2013 ; 8: e67081
75. Kim JE, Kang JS, Lee WJ. Vitamin C induces apoptosis in human colon cancer cell line, HCT-8 via the modulation of calcium influx in endoplasmic reticulum and the dissociation of bad from 14-3-3beta. Immune Netw. 2012 ; 12: 189-195
76. Knowles HJ, Raval RR, Harris AL, Ratcliffe PJ. Effect of ascorbate on the activity of hypoxia-inducible factor in cancer cells. Cancer Res. 2003 ; 63: 1764-1768
77. Kuiper C, Molenaar IG, Dachs GU, Currie MJ, Sykes PH, Vissers MC. Low ascorbate levels are associated with increased hypoxia-inducible factor-1 activity and an aggressive tumor phenotype in endometrial cancer. Cancer Res. 2010 ; 70: 5749-5758
78. Kim J, Lee SD, Chang B, et al. Enhanced antitumor activity of vitamin C via p53 in cancer cells. Free Radic Biol Med. 2012 ; 53: 1607-1615
79. Pollard HB, Levine MA, Eidelman O, Pollard M. Pharmacological ascorbic acid suppresses syngeneic tumor growth and metastases in hormone-refractory prostate cancer. In Vivo. 2010 ; 24: 249-255
80. Espey MG, Chen P, Chalmers B, et al. Pharmacologic ascorbate synergizes with gemcitabine in preclinical models of pancreatic cancer. Free Radic Biol Med. 2011 ; 50: 1610-1619
81. Bowie AG, O'Neill LA. Vitamin C inhibits NF-kappa B activation by TNF via the activation of p38 mitogen-Activated protein kinase. J Immunol. 2000 ; 165: 7180-7188
82. Carcamo JM, Pedraza A, Borquez-Ojeda O, Golde DW. Vitamin C suppresses TNF alpha-induced NF kappa B activation by inhibiting I kappa B alpha phosphorylation. Biochemistry. 2002 ; 41: 12995-13002
83. Kim HN, Kim H, Kong JM, et al. Vitamin C down-regulates VEGF production in B16F10 murine melanoma cells via the suppression of p42/44 MAPK activation. J Cell Biochem. 2011 ; 112: 894-901
84. Mikirova NA, Casciari JJ, Riordan NH. Ascorbate inhibition of angiogenesis in aortic rings ex vivo and subcutaneous Matrigel plugs in vivo. J Angiogenes Res. 2010 ; 2: 2
85. Lee SK, Kang JS, Jung da J, et al. Vitamin C suppresses proliferation of the human melanoma cell SK-MEL-2 through the inhibition of cyclooxygenase-2 (COX-2) expression and the modulation of insulin-like growth factor II (IGF-II) production. J Cell Physiol. 2008 ; 216: 180-188
86. Yeom CH, Lee G, Park JH, et al. High dose concentration administration of ascorbic acid inhibits tumor growth in BALB/C mice implanted with sarcoma 180 cancer cells via the restriction of angiogenesis. J Transl Med. 2009 ; 7: 70
87. Son EW, Mo SJ, Rhee DK, Pyo S. Vitamin C blocks TNF-Alpha-induced NF-kappaB activation and ICAM-1 expression in human neuroblastoma cells. Arch Pharm Res. 2004 ; 27: 1073-1079
88. Klingelhoeffer C, Kammerer U, Koospal M, et al. Natural resistance to ascorbic acid induced oxidative stress is mainly mediated by catalase activity in human cancer cells and catalase-silencing sensitizes to oxidative stress. BMC Complement Altern Med. 2012 ; 12: 61
89. Chen AA, Marsit CJ, Christensen BC, et al. Genetic variation in the vitamin C transporter, SLC23A2, modifies the risk of HPV16-Associated head and neck cancer. Carcinogenesis. 2009 ; 30: 977-981
90. Erichsen HC, Peters U, Eck P, et al. Genetic variation in sodium-dependent vitamin C transporters SLC23A1 and SLC23A2 and risk of advanced colorectal adenoma. Nutr Cancer. 2008 ; 60: 652-659
91. Wright ME, Andreotti G, Lissowska J, et al. Genetic variation in sodium-dependent ascorbic acid transporters and risk of gastric cancer in Poland. Eur J Cancer. 2009 ; 45: 1824-1830
92. Riordan HD, Hunninghake RB, Riordan NH, et al. Intravenous ascorbic acid: protocol for its application and use. P R Health Sci J. 2003 ; 22: 287-290
93. Jackson JA, Hunninghake R, Krier C, Kirby R, Hyland G. Special report: false positive finger stick blood glucose readings after high-dose intravenous vitamin C. J Orthomol Med. 2006 ; 21: 188-190
94. Anderson P.. Paper presented at: Conference of the Oncology Association of Naturopathic Physicians (OncANP) ; Phoenix, AZ ;..
95. Jaipakdee S, Prasongwatana V, Premgamone A, et al. The effects of potassium and magnesium supplementations on urinary risk factors of renal stone patients. J Med Assoc Thai. 2004 ; 87: 255-263
96. Ettinger B, Pak CY, Citron JT, Thomas C, Adams-Huet B, Vangessel A. Potassium-magnesium citrate is an effective prophylaxis against recurrent calcium oxalate nephrolithiasis. J Urol. 1997 ; 158: 2069-2073
97. Sullivan GG, Chen Q, Chen P, Chapman J, Levine M, Drisko JA.. Conference abstract of the Society of Integrative Oncology ; Cleveland, OH ;..
98. Seely D, Stempak D, Baruchel S. A strategy for controlling potential interactions between natural health products and chemotherapy: a review in pediatric oncology. J Pediatr Hematol Oncol. 2007 ; 29: 32-47
99. Kurbacher CM, Wagner U, Kolster B, Andreotti PE, Krebs D, Bruckner HW. Ascorbic acid (vitamin C) improves the antineoplastic activity of doxorubicin, cisplatin, and paclitaxel in human breast carcinoma cells in vitro. Cancer Lett. 1996 ; 103: 183-189
100. Prasad KN, Sinha PK, Ramanujam M, Sakamoto A. Sodium ascorbate potentiates the growth inhibitory effect of certain agents on neuroblastoma cells in culture. Proc Natl Acad Sci U S A. 1979 ; 76: 829-832
101. Prasad SB, Giri A, Arjun J. Use of subtherapeutical dose of cisplatin and vitamin C against murine Dalton's lymphoma. Pol J Pharmacol Pharm. 1992 ; 44: 383-391
102. Reddy VG, Khanna N, Singh N. Vitamin C augments chemotherapeutic response of cervical carcinoma HeLa cells by stabilizing P53. Biochem Biophys Res Commun. 2001 ; 282: 409-415
103. Sarna S, Bhola RK. Chemo-immunotherapeutical studies on Dalton's lymphoma in mice using cisplatin and ascorbic acid: synergistic antitumor effect in vivo and in vitro. Arch Immunol Ther Exp (Warsz). 1993 ; 41: 327-333
104. Taper HS, de Gerlache J, Lans M, Roberfroid M. Non-toxic potentiation of cancer chemotherapy by combined C and K3 vitamin pre-treatment. Int J Cancer. 1987 ; 40: 575-579
105. Casciari JJ, Riordan NH, Schmidt TL, Meng XL, Jackson JA, Riordan HD. Cytotoxicity of ascorbate, lipoic acid, and other antioxidants in hollow fibre in vitro tumours. Br J Cancer. 2001 ; 84: 1544-1550
106. Marian M, Matkovics B. Potentiation of the biological activities of daunomycin and adriamycin by ascorbic acid and dimethylsulfoxide. Experientia. 1982 ; 38: 573-574
107. Wells WW, Rocque PA, Xu DP, Meyer EB, Charamella LJ, Dimitrov NV. Ascorbic acid and cell survival of adriamycin resistant and sensitive MCF-7 breast tumor cells. Free Radic Biol Med. 1995 ; 18: 699-708
108. Verrax J, Calderon PB. Pharmacologic concentrations of ascorbate are achieved by parenteral administration and exhibit antitumoral effects. Free Radic Biol Med. 2009 ; 47: 32-40
109. Martinotti S, Ranzato E, Burlando B. In vitro screening of synergistic ascorbate-drug combinations for the treatment of malignant mesothelioma. Toxicol In Vitro. 2011 ; 25: 1568-1574
110. D'Souza GG, Wang T, Rockwell K, Torchilin VP. Surface modification of pharmaceutical nanocarriers with ascorbate residues improves their tumor-cell association and killing and the cytotoxic action of encapsulated paclitaxel in vitro. Pharm Res. 2008 ; 25: 2567-2572
111. Pathak AK, Singh N, Khanna N, Reddy VG, Prasad KN, Kochupillai V. Potentiation of the effect of paclitaxel and carboplatin by antioxidant mixture on human lung cancer h520 cells. J Am Coll Nutr. 2002 ; 21: 416-421
112. Prasad KN, Hernandez C, Edwards-Prasad J, Nelson J, Borus T, Robinson WA. Modification of the effect of tamoxifen, cis-platin, DTIC, and interferon-Alpha 2b on human melanoma cells in culture by a mixture of vitamins. Nutr Cancer. 1994 ; 22: 233-245
113. Chiang CD, Song EJ, Yang VC, Chao CC. Ascorbic acid increases drug accumulation and reverses vincristine resistance of human non-small-cell lung-cancer cells. Biochem J. 1994 ; 301 (pt 3). 759-764
114. Song EJ, Yang VC, Chiang CD, Chao CC. Potentiation of growth inhibition due to vincristine by ascorbic acid in a resistant human non-small cell lung cancer cell line. Eur J Pharmacol. 1995 ; 292: 119-125
115. Bannerman B, Xu L, Jones M, et al. Preclinical evaluation of the antitumor activity of bortezomib in combination with vitamin C or with epigallocatechin gallate, a component of green tea. Cancer Chemother Pharmacol. 2011 ; 68: 1145-1154
116. Perrone G, Hideshima T, Ikeda H, et al. Ascorbic acid inhibits antitumor activity of bortezomib in vivo. Leukemia. 2009 ; 23: 1679-1686
117. Rosenthal G. Interaction of ascorbic acid and warfarin. JAMA. 1971 ; 215: 1671
118. Feetam CL, Leach RH, Meynell MJ. Lack of a clinically important interaction between warfarin and ascorbic acid. Toxicol Appl Pharmacol. 1975 ; 31: 544-547
119. Sattar A, Willman JE, Kolluri R. Possible warfarin resistance due to interaction with ascorbic acid: case report and literature review. Am J Health Syst Pharm. 2013 ; 70: 782-786